A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 May 2017
At a glance
- Drugs Lurbinectedin (Primary) ; Doxorubicin; Gemcitabine
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 26 Apr 2017 Planned End Date changed from 1 Nov 2022 to 1 Nov 2021.
- 05 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 24 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.